Rapid Sterility Detection in Biologics Manufacturing

A 28-day mycoplasma hold. A 14-to-18-day sterility incubation. For many biologics manufacturers, these numbers are simply the cost of doing business, though for products with short shelf lives or time-sensitive administration windows, the pressure to compress those timelines is considerable. Rapid sterility and mycoplasma detection methods can cut those windows significantly, to under seven days and one to three days respectively, through automated metabolic monitoring and nucleic acid-based detection. Melisa Byrd, Microbiology Supervisor at Element Concord, examines how these methods work and what the science behind them actually looks like.

Why Microbial Testing Timelines Are a Bottleneck in Biologics Manufacturing

Traditional microbial testing methods, while reliable, pose significant challenges in biologics manufacturing. Release testing protocols (including Sterility and Mycoplasma Testing) require 14-28 days – a timeframe that frequently leads to manufacturing bottlenecks and delayed product release. These extended testing periods are especially problematic for therapeutics with short shelf lives. The consequences of these extended test periods include disrupted production workflows, increased inventory hold times, potential product stability concerns, and – most critically – delayed delivery of life-saving treatments to patients. In an environment where speed to market, productivity, and safety underpin organizational health, drug developers must adopt faster, more efficient testing strategies to meet both modern production demands and compliance requirements.

The biologics industry is increasingly turning to alternative approaches that increase testing sensitivity while reducing time-to-result. Rapid detection technologies provide a transformative solution, cutting sterility testing to roughly seven days and mycoplasma testing to just one to three days. However, implementing these methods requires careful consideration of technical, regulatory, and operational factors.

How Rapid Microbial Detection Methods Work

The biologics industry faces unique mycoplasma detection challenges that conventional pharmaceuticals don’t encounter. In protein-based therapeutics, mycoplasma contamination can trigger post-translational modifications, alter glycosylation patterns, and introduce host cell protein impurities—issues that may evade detection in standard potency assays yet significantly impact clinical efficacy and immunogenicity profiles. Regulatory authorities, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), have recognized the limitations of traditional mycoplasma testing for advanced therapies. Their guidance documents acknowledge that conventional 28-day culture methods may be impractical for cell and gene therapy products with inherently short shelf-lives, creating a pathway for alternative method adoption when properly validated.

Nucleic acid-based mycoplasma detection techniques have gained acceptance through validation approaches that demonstrate comparable or superior detection capabilities relative to traditional methods. These molecular methods typically target the highly conserved 16S rRNA gene region found across mycoplasma species known to contaminate biologics manufacturing processes. Implementing rapid methods in biologics manufacturing presents unique challenges. Products with inherent fluorescence, high cell density, or complex formulations often require customized sample preparation protocols to prevent test interference. Method validation must demonstrate effective control of inhibitors through internal amplification controls that verify each individual test’s performance.

The economic benefits of rapid mycoplasma detection are particularly relevant in biologics facilities where manufacturing capacity is limited and valuable. Traditional testing methods that require holding product or production suites for extended periods represent significant opportunity costs and can impact manufacturing schedules across multiple products. Contract development and manufacturing organizations supporting biologics production increasingly offer rapid mycoplasma testing approaches that have been validated across common expression systems and manufacturing processes. This availability helps biopharmaceutical companies implement advanced methods while managing regulatory considerations effectively.

Why Biologics Present Unique Microbial Testing Challenges

The implications of traditional testing timelines extend throughout the manufacturing process, disrupting production schedules and complicating inventory management. Standard sterility testing, per USP <71>, requires a minimum 14-day incubation period, with a potential extension to 18 days when subculturing is necessary. In the case of products with high cell counts or inherent turbidity, the additional subculture step adds days to an already lengthy testing timeline. This requirement applies to substances, preparations, and articles which, according to the pharmacopeia, must be sterile – encompassing everything from parenteral preparations to ophthalmic products.

For mycoplasma testing, traditional culture methods demand a minimum of 28 days testing length for definitive results, involving both agar and broth culture methods with multiple intermediate checks. These extended testing periods significantly impact inventory management, manufacturing scheduling, and facility utilization efficiency.

Beyond timeline considerations, traditional methods present additional technical constraints. These methods often demand large sample volumes - problematic for high-value biologics, where every milliliter represents significant value. Limited opportunity for in-process testing reduces the ability to detect contamination events early in the manufacturing process. Product matrix effects may necessitate additional subculture steps, creating further delays in the availability of results.

Where appropriate, the use of rapid microbial detection methods help mitigate these risks by enabling real-time decision-making and improving process efficiency.

“There are several reasons why rapid sterility may not be suitable for organizations to implement in-house, including the need to meet specific validation criteria, lengthy method validation process, complex therapy workflows, and cost and resources associated with new equipment, training, and validation efforts,” explains Melisa Byrd, Microbiology Supervisor at Element Concord. In her experience supporting these programs, Byrd notes that “Most of the drug developers we engage are looking to gain efficiencies in expediting product route to market while keeping key resources focused on growing their pipeline and maintaining a favorable cost profile. And that’s exactly where working with an experienced testing partner can help.”

How Faster Microbial Testing Improves Biologics Manufacturing Operations

Modern rapid detection methods improve speed and reliability, employing various analytical principles to achieve faster, more reliable contamination detection. Each technology offers distinct advantages for specific applications, requiring careful evaluation for specific product types and manufacturing processes.

Rapid Sterility Testing via Respiration Detection

Respiration detection technology enables continuous monitoring of microbial metabolism through the measurement of CO₂ production. Advanced automated systems maintain precise environmental conditions in separate chambers for aerobic and anaerobic organisms. The technology utilizes sophisticated monitoring capabilities with automated data management, ensuring complete traceability from sample preparation through final reporting.

The automated nature of detection significantly reduces time-to-result compared to traditional methods. While conventional testing requires 14-18 days, respiration detection has the ability to deliver results in less than 7 days. This improvement stems from continuous monitoring capabilities combined with the elimination of subjective visual inspection steps. An integrated barcode tracking system provides complete traceability from sample preparation to final reporting, ensuring data integrity.

Key Takeaways

• Traditional sterility and mycoplasma testing methods require 14–28 days of incubation, creating significant manufacturing bottlenecks, particularly for biologics with short shelf lives or time-sensitive administration requirements.
• Rapid detection approaches, including respiration-based sterility testing and nucleic acid-based mycoplasma detection, can compress these timelines to under 7 days and 1–3 days respectively, when properly validated.
• Biologics products present unique interference challenges, including inherent fluorescence, high cell density, and complex formulations, that require product-specific sample preparation and validation strategies.
• Transitioning to rapid methods involves technical, regulatory, and operational preparation; understanding your product's characteristics and the applicable regulatory framework is the foundation for a sound implementation strategy.

For a comprehensive technical reference covering rapid detection methods in biologics quality control, download the full white paper: “Breaking Through the Testing Bottleneck: How Rapid Detection Methods Are Modernizing Quality Control in Biologics Manufacturing.”

Element’s microbiology testing team provides rapid sterility and mycoplasma detection services with validated methods designed to support biologics release testing workflows. To discuss your testing requirements, contact the Element team. Learn more about Element's testing expertise and global laboratory network on our About Element page.